Since both, dasatinib and ponatinib also target ABL kinase, and dasatinib, WH-4-023, Ponatinib target the SRC kinase, our finding reveals that the high-ELF4 cancers are likely to signal through SRC and ABL kinases. Here, ABL1 is linked to cancer.